Study Summary
This trial is testing a new medicine (Mim8) to prevent bleeding episodes in people with haemophilia A who have or don’t have inhibitors. Participants will get up to 262 injections of Mim8 over 5.5 years, with restrictions on other medicines.
- Hemophilia A With Inhibitors
- Hemophilia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: From visit 8 (week 26) until end of treatment (up to 262 weeks)
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Arm 1
1 of 2
Arm 2
1 of 2
Experimental Treatment
425 Total Participants · 2 Treatment Groups
Primary Treatment: Arm 1 · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
On what scale is this clinical trial being conducted?
"Currently, 4 distinct medical facilities are involved in this research. These include Chicago, Iowa City and Dayton among others. To limit the need for travel during participation, it is beneficial to select a clinic near your area of residence." - Anonymous Online Contributor
What potential risks does Arm 1 pose to participants?
"Arm 1 was assigned a score of 3, indicating its safety is supported by prior clinical data and multiple rounds of evidence." - Anonymous Online Contributor
Is enrollment still ongoing for this experiment?
"According to the clinicaltrials.gov database, this trial is no longer actively seeking applicants as its last update was on January 19th 2023. Despite this, there are 90 other research studies that are currently enrolling patients." - Anonymous Online Contributor